Adaptimmune Therapeutics plc (ADAP) ADS

Sell:$0.06Buy:$0.06$0.01 (14.51%)

Prices delayed by at least 15 minutes
Sell:$0.06
Buy:$0.06
Change:$0.01 (14.51%)
Deal now
Prices delayed by at least 15 minutes
Sell:$0.06
Buy:$0.06
Change:$0.01 (14.51%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.

Key people

Adrian Rawcliffe
Chief Executive Officer, Director
Gavin Hilary James Wood
Chief Financial Officer
William C. Bertrand
Chief Operating Officer
Joanna Brewer
Chief Scientific Officer
John Lunger
Chief Patient Supply Officer
David M. Mott
Non-Executive Independent Chairman of the Board
Andrew Allen
Non-Executive Independent Director
Lawrence M. Alleva
Non-Executive Independent Director
Ali Behbahani
Non-Executive Independent Director
John P. Furey
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    ADAP
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US00653A1079
  • Market cap
    $15.37m
  • Employees
    506
  • Shares in issue
    1.59bn
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.